These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 8016121)

  • 21. Mammalian p53 can function as a transcription factor in yeast.
    Schärer E; Iggo R
    Nucleic Acids Res; 1992 Apr; 20(7):1539-45. PubMed ID: 1579447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein.
    Bargonetti J; Manfredi JJ; Chen X; Marshak DR; Prives C
    Genes Dev; 1993 Dec; 7(12B):2565-74. PubMed ID: 8276239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization.
    Iwabuchi K; Li B; Bartel P; Fields S
    Oncogene; 1993 Jun; 8(6):1693-6. PubMed ID: 8502489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity.
    Bayle JH; Elenbaas B; Levine AJ
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5729-33. PubMed ID: 7777576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discrimination of DNA binding sites by mutant p53 proteins.
    Thukral SK; Lu Y; Blain GC; Harvey TS; Jacobsen VL
    Mol Cell Biol; 1995 Sep; 15(9):5196-202. PubMed ID: 7651437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The interaction between p53 and DNA topoisomerase I is regulated differently in cells with wild-type and mutant p53.
    Gobert C; Skladanowski A; Larsen AK
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10355-60. PubMed ID: 10468612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
    Di Como CJ; Prives C
    Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region.
    Srinivasan R; Maxwell SA
    Oncogene; 1996 Jan; 12(1):193-200. PubMed ID: 8552392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction of p53 with its consensus DNA-binding site.
    Wang Y; Schwedes JF; Parks D; Mann K; Tegtmeyer P
    Mol Cell Biol; 1995 Apr; 15(4):2157-65. PubMed ID: 7891710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular interactions between telomerase and the tumor suppressor protein p53 in vitro.
    Li H; Cao Y; Berndt MC; Funder JW; Liu JP
    Oncogene; 1999 Nov; 18(48):6785-94. PubMed ID: 10597287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A movable and regulable inactivation function within the central region of a temperature-sensitive p53 mutant.
    Chuang JY; Lin CT; Wu CW; Lin YS
    J Biol Chem; 1995 Oct; 270(41):23899-902. PubMed ID: 7592577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Precise mapping of the tms1 binding site on p53.
    Wagner P; Fuchs A; Prowald A; Montenarh M; Nastainczyk W
    FEBS Lett; 1995 Dec; 377(2):155-8. PubMed ID: 8543040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
    Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
    Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.
    Bergamaschi D; Samuels Y; O'Neil NJ; Trigiante G; Crook T; Hsieh JK; O'Connor DJ; Zhong S; Campargue I; Tomlinson ML; Kuwabara PE; Lu X
    Nat Genet; 2003 Feb; 33(2):162-7. PubMed ID: 12524540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53.
    Friedler A; Veprintsev DB; Rutherford T; von Glos KI; Fersht AR
    J Biol Chem; 2005 Mar; 280(9):8051-9. PubMed ID: 15611070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of a single plasmid-based modified yeast one-hybrid system for investigation of in vivo protein-protein and protein-DNA interactions.
    Chen G; DenBoer L; Shin J
    Biotechniques; 2008 Sep; 45(3):295-304. PubMed ID: 18778253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein.
    Freeman J; Schmidt S; Scharer E; Iggo R
    EMBO J; 1994 Nov; 13(22):5393-400. PubMed ID: 7957105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of cellular proteins that bind the central conserved region of p53.
    Takimoto M; Sermsuvitayawong K; Matsubara K
    Biochem Biophys Res Commun; 1994 Jul; 202(1):490-6. PubMed ID: 8037753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
    Mansur CP; Marcus B; Dalal S; Androphy EJ
    Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PACT: cloning and characterization of a cellular p53 binding protein that interacts with Rb.
    Simons A; Melamed-Bessudo C; Wolkowicz R; Sperling J; Sperling R; Eisenbach L; Rotter V
    Oncogene; 1997 Jan; 14(2):145-55. PubMed ID: 9010216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.